Rosenbaum David P.
Known title: Chief Development OfficerCIK: 0001611311
Rosenbaum David P.'s purchase track record
Rosenbaum David P. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 4,941 | $24K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,243 | $11K | 11/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 27,171 | $166K | 11/6/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 27,171 | $63K | 11/6/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 27,172 | $63K | 11/4/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 27,172 | $162K | 11/4/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 49,564 | $343K | 9/27/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,312 | $33K | 9/13/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,969 | $29K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,250 | $13K | 8/20/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 20,507 | $20K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 20,507 | $123K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 20,000 | $119K | 8/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 17,872 | $125K | 6/3/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 4,855 | $38K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,198 | $17K | 5/21/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,183 | $48K | 2/26/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,017 | $44K | 2/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,294 | $20K | 2/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 15,344 | $141K | 2/8/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 112,750 | $0 | 1/16/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 70,120 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 30,000 | $199K | 1/8/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 5,675 | $34K | 12/18/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 7,000 | $39K | 12/14/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 20,000 | $105K | 12/8/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 10,272 | $51K | 12/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,000 | $14K | 11/30/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,835 | $12K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 932 | $4K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,644 | $7K | 10/10/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,897 | $13K | 9/8/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,846 | $10K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 937 | $3K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,835 | $10K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 934 | $3K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,000 | $14K | 3/29/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,394 | $10K | 2/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,114 | $3K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 25,325 | $0 | 1/5/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 78,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 26 | $50 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 33 | $64 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,405 | $3K | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 11 | $21 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 2 | $4 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 471 | $918 | 11/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,000 | $3K | 9/1/2022 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,441 | $1K | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 17 | $17 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 496 | $488 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1 | $1 | 8/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 43,093 | $28K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 911 | $579 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 17,270 | $11K | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 366 | $233 | 6/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,489 | $1000 | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 524 | $352 | 5/20/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,752 | $1K | 2/22/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 601 | $403 | 2/22/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 15,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▲ Buy | Grant | 40,000 | $0 | 1/6/2022 | View on chart |
| ARDX | ▼ Sell | Open Market | 643 | $638 | 11/22/2021 | View on chart |
| ARDX | ▼ Sell | Open Market | 184 | $182 | 11/22/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 60,000 | $0 | 10/8/2021 | View on chart |
| ARDX | ▲ Buy | Grant | 150,000 | $0 | 10/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.